Search results for "LYMPHOMA"

showing 10 items of 707 documents

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

2012

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to g…

Oncologymedicine.medical_specialtybusiness.industryFirst linemantle cell lymphomaCancerTreatment optionsmTOR-inhibitorReviewDiseasemedicine.diseaseBioinformaticslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TemsirolimusClinical knowledgeOncologyInternal medicinetemsirolimusmedicineRefractory Mantle Cell LymphomaMantle cell lymphomabusinessmedicine.drugClinical Medicine Insights: Oncology
researchProduct

The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma

2014

Interleukin (IL)-31A binds to an heterodimer composed of IL-31 receptor A (IL-31RA) and Oncostatin M Receptor (OSMR). The IL-31/IL-31R complex is involved in the pathogenesis of various skin diseases, including cutaneous T-cell lymphoma. No information is available on the relations between the IL-31/IL-31R complex and B-cell lymphoma. Here we have addressed this issue in follicular lymphoma (FL), a prototypic germinal center(GC)-derived B-cell malignancy. IL-31 enhanced primary FL cell proliferation through IL-31R-driven signal transducer and activator of transcription factor 1/3 (STAT1/3), extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation. In contrast, GC B cells d…

MaleSTAT3 Transcription Factormedicine.medical_specialtyCancer ResearchPrimary Cell CultureFollicular lymphomaBiologyParacrine signallingCytosolCell-Derived MicroparticlesInternal medicinemedicineHumansProtein IsoformsPhosphorylationAutocrine signallingLymphoma FollicularCell ProliferationMitogen-Activated Protein Kinase 1B-LymphocytesMitogen-Activated Protein Kinase 3Gene Expression Regulation LeukemicInterleukinsMicrovesicleMedicine (all)Cell MembraneB-LymphocyteGerminal centerOncostatin M receptorInterleukinProtein IsoformReceptors InterleukinHematologyInterleukinMiddle Agedmedicine.diseaseGerminal CenterMolecular biologyCell-Derived MicroparticleEndocrinologySTAT1 Transcription FactorAnesthesiology and Pain MedicineOncologyFemaleSignal transductionNeoplasm GradingProto-Oncogene Proteins c-aktHumanSignal Transduction
researchProduct

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diff use large B-cell lymphoma: comparison b…

2015

Summary Background Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collab…

AdultMalePathologymedicine.medical_specialtyPediatricsAdolescent[SDV]Life Sciences [q-bio]Follicular lymphomaAutopsyNOminimum clinical recommendations03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicinefollow upHumans030212 general & internal medicineYoung adultcancer survivalLymphoma FollicularNon-Hodgkin lymphomaAgedHematologyWalesminimum clinical recommendations Non-Hodgkin lymphoma relative survival cancer survival follow upbusiness.industryCancerrelative survivalHematologyMiddle Agedmedicine.disease3. Good healthLymphoma[SDV] Life Sciences [q-bio]EuropeScotland030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomaInternational Classification of Diseases for Oncology
researchProduct

Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.

2015

Abstract Background: Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms, and selected mature B-cell neoplasms is reported. Method: Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium (1988–2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944,…

OncologyAdultMalemedicine.medical_specialtyEpidemiologyChronic lymphocytic leukemiamedicine.medical_treatmentFollicular lymphomaBiologyArticleBody Mass IndexYoung Adultimmune system diseasesRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseLymphangiogenesisAdiposityAgedRetrospective StudiesPolymorphism GeneticAbsolute risk reductionDNA NeoplasmMiddle Agedmedicine.diseaseObesityLymphomaCytokineOncologyIL1AImmunologyCytokinesFemaleLymphoma Large B-Cell DiffuseBody mass indexCancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
researchProduct

Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongo…

2011

Abstract Abstract 2638 We recently demonstrated that over 30% of cases with splenic marginal-zone lymphoma (SMZL) express distinctive immunoglobulin (IG) receptors that utilize a single polymorphic variant of the IGHV1-2 gene (IGHV1-2*04) and also exhibit restricted antigen-binding site motifs and precise targeting of somatic hypermutation (SHM). On these grounds, we proposed the existence of molecular subtypes of SMZL defined by immunogenetic analysis of the IG receptors with implications for selection by specific (super) antigenic element(s) in the development of at least a major subset of SMZL. In order to gain insight as to whether antigen involvement is relevant only prior to the malig…

GeneticsImmunologySomatic hypermutationCell BiologyHematologyComplementarity determining regionBiologymedicine.diseaseBiochemistryGermlineSubcloningmedicinebiology.proteinSplenic marginal zone lymphomaAntibodyIGHV@GeneBlood
researchProduct

Functioning of family system in pediatric oncology during treatment phase.

2012

The study focuses on parents’ psychological implications caused by the treatment of their children suffering from tumor. It investigates some specific mothers’ resource factors such as their strategies of coping and the perception of their own family functioning in terms of cohesion and adaptability. The study was performed with 34 mothers of children suffering from acute lymphoblastic leukemia(ALL),duringthetreatmentphase.TheusedtoolsweretheCopingOrientationtoProblem Experienced—New Italian Version, to investigate coping strategies, and the Family Adaptability and Cohesion Evaluation Scale-III, to analyze both real and ideal perception of family functioning. The data related to coping, show h…

MaleCoping (psychology)media_common.quotation_subjectLymphoblastic LeukemiaFamily functioningcompliance coping behavior family pediatric oncology psychology/psychiatry quality of life/psychosocial treatmentMothersMedical OncologyPediatricsAdaptabilityDevelopmental psychologySocial supportPerceptionAdaptation PsychologicalAntineoplastic Combined Chemotherapy ProtocolsPediatric oncologyMedicineHumansChildmedia_commonFamily Healthbusiness.industrySocial SupportHematologyPrecursor Cell Lymphoblastic Leukemia-LymphomaOncologyPediatrics Perinatology and Child HealthAptitudeFemalebusinessPediatric hematology and oncology
researchProduct

Fatal sepsis due to mycobacterium tuberculosis after allogeneic bone marrow transplantation.

2001

Mycobacterium tuberculosis is a serious, but rare infectious complication after allogeneic bone marrow transplantation. We describe a case of fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation for Philadelphia chromosome-positive ALL. The diagnosis was made after BAL. Although broad-spectrum antituberculous therapy was started immediately after diagnosis, blood cultures became positive for Mycobacterium tuberculosis. The patient developed severe pyrexias and finally died of multi-organ failure. Rapid progression of mycobacterial infection should be considered in patients post BMT with unexplained fever, particularly in patients from endemic areas.

AdultMaleMycobacterium tuberculosisSepsisFatal OutcomeAcute lymphocytic leukemiamedicineHumansTransplantation HomologousTuberculosisIn patientAutogenous boneBone Marrow TransplantationTransplantationbiologybusiness.industryMarrow transplantationHematologyMycobacterium tuberculosisPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseasebiology.organism_classificationmedicine.anatomical_structureImmunologyBone marrowbusinessComplicationBone marrow transplantation
researchProduct

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

2021

Abstract In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly in patients with severely impaired immune system. In response to that uncertainty, the Spanish Society of Hematology and Hemotherapy launched an initiative aimed to provide recommendations for vaccination of the main hematological conditions. This document is based on the available information on COVID-19 outcomes, prior knowledge on vaccination in hematological patients, recent pu…

Cancer Researchmedicine.medical_specialtyCOVID-19 VaccinesConsensusCoronavirus disease 2019 (COVID-19)myeloproliferative neoplasmSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)lymphomaReviewstem cell transplantationCOVID-19 SARS-CoV-2 vaccine acute leukemia allogeneic stem cell transplantation lymphoma myelodisplastic syndrome myeloproliferative neoplasm onco-hematology stem cell transplantation vaccination consensusallogeneic stem cell transplantationSARS-CoV-2 vaccineInternal medicinePandemicmedicineHemotherapyHumansIn patientacute leukemiaIntensive care medicineExpert TestimonyPandemicsonco-hematologyHematologySARS-CoV-2business.industryVaccinationCOVID-19Expert consensusHematologyVaccinationvaccination consensusOncologymyelodisplastic syndromebusiness
researchProduct

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

2011

Abstract Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes (extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and splenic MZLs). Nevertheless, the relationship between the subtypes is still unclear. We performed a comprehensive analysis of genomic DNA copy number changes in a very large series of MZL cases with the aim of addressing this question. Samples from 218 MZL patients (25 nodal, 57 MALT, 134 splenic, and 2 not better specified MZLs) were analyzed with the Affymetrix Human Mapping 250K SNP arrays, and the data combined with matched gene expression in 33 of 218 cases. MALT lymphoma presented significantly more frequently gain…

MalePathologyLymphomaMarginal ZoneBiochemistryExtranodal Diseaseclassification/genetics/pathologyhemic and lymphatic diseases80 and overgeneticsAged 80 and overComparative Genomic HybridizationGenomeMALT lymphomaHematologySingle NucleotideMiddle AgedMarginal zonePrognosisGene Expression Regulation NeoplasticAdult Aged Aged; 80 and over Chromosome Aberrations Comparative Genomic Hybridization DNA Fingerprinting Female Gene Expression Profiling Gene Expression Regulation; Neoplastic Genome; Human Humans Lymphoma; B-Cell; Marginal Zone; classification/genetics/pathology Male Middle Aged Polymorphism; Single Nucleotide; genetics Prognosis Splenic Neoplasms; classification/genetics/pathology Young AdultFemaleHumanAdultmedicine.medical_specialtyGenome-wide DNA profilingImmunologyBiologyPolymorphism Single NucleotideYoung AdultGenome-wide DNA profiling; marginal zone lymphomas; clinical outcome.medicineSNPHumansSplenic marginal zone lymphomaPolymorphismAgedChromosome AberrationsNeoplasticGenome HumanSplenic Marginal Zone Lymphoma; GenomicGene Expression ProfilingSplenic NeoplasmsB-CellLymphoma B-Cell Marginal ZoneCell Biologyclinical outcome.medicine.diseasemarginal zone lymphomaDNA FingerprintingLymphomaGene expression profilingGene Expression RegulationComparative genomic hybridization
researchProduct